Prelude Therapeutics Incorporated
- Open
- 5.32
- Day high
- 5.36
- Day low
- 4.90
- Prev close
- 5.33
- Volume
- 238K
- Mkt cap
- $395M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 6.6
- P/S
- 23.6
- Yield
- —
- Per share
- —
- ▲Insiders net buying $25.0M over the last 3 months (6 open-market buys, 0 sales)
- ◆Cluster buying — multiple insiders bought within days
- 🏛Institutions accumulating (13F)
Prelude Therapeutics Incorporated (PRLD) is a Healthcare company listed on NASDAQ. The stock is up 566% over the past year. Over the trailing 3 months, insiders filed 6 open-market buys and 0 sales (SEC Form 4).
Prelude Therapeutics Incorporated (PRLD) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PRLD earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-0.27 | $-0.13 | +51.9% | $5M | +0.0% |
| Mar 10, 2026 | $-0.03 | $-0.20 | -566.7% | $6M | -72.5% |
| Nov 12, 2025 | $-0.35 | $-0.26 | +25.7% | $7M | -68.3% |
| Aug 14, 2025 | $-0.45 | $-0.41 | +8.9% | — | — |
| Mar 10, 2025 | $-0.49 | $-0.38 | +22.4% | $4M | — |
| Feb 15, 2024 | $-0.50 | $-0.47 | +6.0% | $3M | — |
| Nov 1, 2023 | $-0.58 | $-0.45 | +22.4% | — | — |
| Aug 3, 2023 | $-0.65 | $-0.54 | +16.9% | — | — |
| Mar 15, 2023 | $-0.63 | $-0.60 | +4.8% | — | — |
| Nov 14, 2022 | $-0.63 | $-0.63 | +0.0% | — | — |
| Mar 16, 2022 | $-0.69 | $-0.71 | -2.9% | — | — |
| Nov 12, 2021 | $-0.62 | $-0.66 | -6.5% | — | — |
PRLD insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 10, 2026 | Dorton Katinadirector | Grant | 38,000 | $3.94 |
| Jun 10, 2026 | BAKER BROS. ADVISORS LPdirector, 10 percent owner: | Grant | 38,000 | $3.94 |
| Jun 10, 2026 | FRIEDMAN PAUL Adirector | Grant | 38,000 | $3.94 |
| Jun 10, 2026 | Sandor Victordirector | Grant | 38,000 | $3.94 |
| Jun 10, 2026 | Bonita David Pdirector, 10 percent owner: | Grant | 38,000 | $3.94 |
| Jun 10, 2026 | Babler Martindirector | Grant | 38,000 | $3.94 |
| May 4, 2026 | Morris Charles Qofficer: Chief Medical Officer | Grant | 450,000 | $4.70 |
| Apr 23, 2026 | ORBIMED ADVISORS LLCdirector, 10 percent owner: | Buy | 1,689,189 | $4.44 |
| Apr 23, 2026 | ORBIMED ADVISORS LLCdirector, 10 percent owner: | Buy | 1,126,126 | $4.44 |
| Apr 23, 2026 | Bonita David Pdirector, 10 percent owner: | Buy | 1,689,189 | $4.44 |
| Apr 23, 2026 | Bonita David Pdirector, 10 percent owner: | Buy | 1,126,126 | $4.44 |
| Apr 22, 2026 | BAKER BROS. ADVISORS LPdirector, 10 percent owner: | Buy | 114,601 | $0.00 |
| Apr 22, 2026 | BAKER BROS. ADVISORS LPdirector, 10 percent owner: | Buy | 2,137,651 | $0.00 |
| Feb 5, 2026 | Lim Bryant Davidofficer: CLO, CFO, Corp Sec. | Grant | 275,000 | $2.30 |
| Feb 5, 2026 | Combs Andrewofficer: Chief Chemistry Officer | Grant | 230,000 | $2.30 |
Source: PRLD SEC Form 4 filings, latest Jun 10, 2026. For informational purposes only — not investment advice.
See the full PRLD insider & 13F page →Prelude Therapeutics Incorporated company profile
Overview
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is a clinical-stage precision oncology company founded in 2016 and headquartered in Wilmington, Delaware. The company went public in September 2020 and focuses on discovering and developing novel precision cancer medicines targeting underserved patient populations. Prelude operates in the biotechnology sector, specifically concentrating on developing targeted therapies for various cancer types through a precision medicine approach that aims to match specific treatments to patients based on their tumor's genetic characteristics.
Business
Prelude Therapeutics operates in the precision oncology biotechnology industry, which represents a specialized segment of cancer drug development. Unlike traditional chemotherapy that broadly attacks rapidly dividing cells, precision oncology focuses on developing targeted therapies that specifically attack cancer cells based on their unique genetic mutations or protein expressions while sparing healthy cells. The company's core business revolves around developing small molecule inhibitors - chemical compounds that can block specific proteins involved in cancer cell growth and survival. These inhibitors are designed to target particular molecular pathways that cancer cells depend on, offering potentially more effective treatments with fewer side effects than conventional chemotherapy. Prelude's pipeline consists of several drug candidates at various stages of development. PRT543 is currently in Phase 1 clinical trials for select solid tumors and myeloid malignancies, targeting a protein involved in gene regulation. PRT811 is also in Phase 1 trials for solid tumors, including glioblastoma multiforme, one of the most aggressive forms of brain cancer. The company is developing PRT1419, which targets anti-apoptotic proteins that help cancer cells avoid programmed cell death, and PRT2527, a selective inhibitor of CDK9, a protein involved in gene transcription. Additionally, Prelude has several preclinical programs including PRT-SCA2 for genomically selected cancers, PRT3645 for brain-penetrant CDK4/6 inhibition, and PRT-K4 for solid tumors. The company operates as a single business segment focused entirely on oncology drug development, with no current commercial products generating significant revenue.
Revenue model
Prelude Therapeutics currently generates minimal revenue as it remains in the clinical development stage with no approved commercial products. The company's limited revenue of $7 million in 2024 appears to come from research collaborations or licensing agreements rather than product sales. As a typical biotech development company, Prelude operates on a high-risk, high-reward business model where substantial upfront investments in research and development are made with the expectation of future returns from successful drug approvals and commercialization. The company's future revenue model will likely depend on several potential streams: direct product sales following regulatory approval, licensing agreements with larger pharmaceutical companies, milestone payments from development partnerships, and potential royalty income from licensed technologies. The paying customers would ultimately be healthcare systems, hospitals, oncology clinics, and patients through insurance coverage, but this revenue realization is years away pending successful clinical trials and regulatory approvals. Several factors significantly impact the company's financial prospects and margins. Regulatory approval success rates represent the most critical factor, as failure in clinical trials can eliminate entire revenue streams and require substantial write-offs of development costs. Competition from other precision oncology companies and established pharmaceutical giants developing similar targeted therapies could reduce market share and pricing power. Healthcare reimbursement policies and insurance coverage decisions will directly affect accessibility and pricing of future products. Manufacturing and scaling costs will impact gross margins once products reach commercialization. Additionally, patent protection strength and duration will determine the company's ability to maintain exclusivity and premium pricing, while clinical trial costs and timelines continue to pressure current cash burn rates and overall development economics.
Competitive moat
Prelude Therapeutics operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages at this stage of development. The company's primary potential moat lies in its proprietary drug discovery platform and specific molecular targets, but these advantages are relatively narrow and time-limited. The company's intellectual property portfolio around its specific drug candidates provides some protection, but patents in biotechnology typically offer 15-20 years of exclusivity from filing date, and much of this time is consumed during the lengthy development and approval process. Prelude's focus on precision oncology targeting specific genetic mutations could create some differentiation, but this approach is increasingly common across the industry. The company faces significant competitive threats from multiple directions. Large pharmaceutical companies like Roche, Bristol Myers Squibb, and Pfizer have substantially greater resources for drug development and can pursue similar targets with larger research teams and deeper pockets. Numerous other clinical-stage biotech companies are developing competing precision oncology therapies, creating a crowded field where multiple companies may target the same pathways or patient populations. Additionally, the rapid pace of scientific advancement in oncology means that breakthrough therapies from competitors could potentially obsolete Prelude's pipeline before its drugs reach market. The company's small size and limited resources make it vulnerable to being outpaced by better-funded competitors or acquired by larger players seeking to consolidate promising assets. Overall, Prelude's competitive position is relatively weak, relying primarily on execution excellence and some degree of scientific luck rather than durable structural advantages. The company's survival and success will largely depend on achieving positive clinical trial results faster and more efficiently than competitors pursuing similar approaches.
Risks & safety
Prelude Therapeutics presents significant financial risks with limited margin of safety for investors, though the company maintains adequate short-term liquidity. • Cash burn and solvency: The company burned $103.7 million in free cash flow during 2024, with quarterly burn rates around $25-35 million. With only $40.3 million in cash and short-term investments as of Q1 2025, the company faces a potential cash runway of approximately 4-6 quarters at current burn rates, creating near-term financing pressure. • Debt levels: Debt-to-equity ratio remains manageable at 0.17, indicating relatively low financial leverage. Current ratio of 5.18 shows strong short-term liquidity position relative to immediate obligations. • Valuation metrics: Trading at 0.57x book value suggests potential asset-based value, though much of book value consists of intangible research assets of uncertain worth. Negative earnings make traditional valuation metrics less meaningful. • Other considerations: The company's $58 million market capitalization appears low relative to its asset base, but clinical-stage biotech valuations are highly speculative and dependent on binary trial outcomes. The Graham net-net ratio of 0.80 suggests potential deep value characteristics, though this may reflect market skepticism about asset quality rather than opportunity.
Recent development
Based on the available financial data, Prelude Therapeutics has been advancing its clinical pipeline over recent years, though specific strategic developments are limited without detailed earnings call transcripts. The company has maintained its focus on precision oncology with multiple drug candidates progressing through clinical trials. The emergence of some revenue in 2024 ($7 million compared to zero in previous years) suggests the company may have entered into research collaborations or licensing agreements, representing a potential strategic shift toward partnership-based development models. This could indicate management's recognition of the need for external capital and expertise to advance their pipeline more efficiently. The company's cash position has declined significantly from over $235 million in current assets at the end of 2023 to approximately $135 million by the end of 2024, reflecting the substantial ongoing investment in clinical development activities. This cash consumption pattern suggests the company has been actively advancing its clinical programs, particularly the Phase 1 trials for PRT543 and PRT811. The maintenance of a diverse pipeline across multiple cancer types and molecular targets indicates a strategy of risk diversification, allowing the company to pursue multiple shots-on-goal rather than betting everything on a single therapeutic approach. However, this broad approach also spreads limited resources across multiple programs, potentially slowing overall development timelines.
PRLD company profile · for informational purposes only — not investment advice.
Track PRLD with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free